CS
UBX

Credit Suisse’s Unity Biotechnology UBX Stock Holding History

Credit Suisse’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,477
Closed -$128K – 4132
2020
Q2 		$128K Buy
+1,477
New +$110K ﹤0.01% 3811
2020
Q1 		– Sell
-1,799
Closed -$129K – 4248
2019
Q4 		$129K Buy
1,799
+309
+21% +$21.8K ﹤0.01% 4052
2019
Q3 		$91K Buy
+1,490
New +$105K ﹤0.01% 3980

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse's UBX Position: Q3 2020 in Review

Credit Suisse sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 1,477 shares — an estimated $128K sold.

Credit Suisse first reported a position in UBX in Q3 2019 and held it in 3 quarters. The position peaked at $129K in Q4 2019. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

  • Credit Suisse reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Credit Suisse sold 1,477 Unity Biotechnology shares in Q3 2020, an estimated $128K.
  • Credit Suisse first reported a position in Unity Biotechnology in Q3 2019 and held it in 3 quarters.
  • Credit Suisse's Unity Biotechnology position peaked at $129K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Credit Suisse's 13F filing for Q3 2020, filed 13 Nov 2020.